Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce fast-dissolving oral thin-film products for pharmaceutical and healthcare markets, potentially generating up to $15 million in revenue within 18 months after equipment qualification. The move supports Callan JMB's strategy to strengthen healthcare supply chains and create new high-margin revenue streams without needing additional capital. This technology meets growing demand for alternative drug delivery formats and enhances the company's healthcare logistics and manufacturing platform.
Callan JMB's new QuickStrip™ oral thin-film production line is projected to generate $15 million in revenue over 18 months. For readers following the health sector, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US health stocks, 82 rose and 47 fell. Among notable movers, MRVI gained 2.82% to USD 8.03 with a typical hold time of 14 days, contrasting with MMED which dropped 2.95% to USD 17.74 and a shorter hold time of 13 days, while BNGO rose 2.61% to USD 1.18 with the longest hold time of 52 days.
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Tigo Energy, Fluence Energy, and Anavex Life Sciences. The lawsuits allege these companies made false or misleading stat...
Alvotech, a global biotech company specializing in biosimilars, announced its management team will participate in several investor conferences in November 2026, including events in London, Oslo, and Stockholm. These presentations and fireside chats w...
